Moshe Weinstein,



Moshe joined Moebius in December 2015, and brings with him over 15 years of business experience. Prior to joining Moebius, Moshe spent 7 years at Novartis in the US and Latin America where he held positions of increasing responsibility in business development & licensing, sales, marketing and commercial management. Prior to Novartis, Moshe served as a consultant for PricewaterhouseCoopers. Moshe earned an MBA from INSEAD, and has a bachelors in business & management from Yeshiva University in New York.


Dr. Yaniv Dolev,


Founder & COO

Yaniv founded Moebius in 2008 and served as the company’s CEO from its foundation until December 2015. Yaniv was responsible for the development and successful clinical trial of MM-II, and led the company through a series of fundraising rounds. Yaniv trained as a Veterinary Surgeon at the Faculty of Veterinary Science, National University of La Plata, Argentina, where he specialized in equine orthopedics. He earned an M.B.A. from the School of Macro-Economic Studies, Buenos Aires, Argentina.


Dr. Maty Ayal-Hershkovitz,



Maty joint Moebius in September 2013, and brings with her over 20 years of experience in pharmaceutical biotechnology. Maty is an expert in biopharmaceuticals process development, quality systems establishment, inspections and training, complex technologies transfer and CMC. Prior to joining Moebius, Maty held positions of Process Development Manager, Head of Technology Transfer, Quality Assurance and Regulatory Affairs Manager. Maty has a Ph.D. in Biological Chemistry from the Hebrew University in Jerusalem and spent 4 years as a post-doctoral fellow in the Beckman Research Institute of City of Hope, California.


Prof. Chezy Barenholz,


Inventor & Board Member

Yechezkel “Chezy” Barenholz, Ph.D. is the head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry, at the Hebrew University, Hadassah Medical School, Jerusalem, Israel. Dr. Barenholz is a world renowned specialist in lipids and membranes, and is on the Editorial Boards of Chemistry and Physics of Lipids and the Journal of Liposome Research. He is one of the key inventors of DOXIL, a liposomal formulation of doxorubicin for cancer treatment, marketed by Johnson & Johnson.